<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137187</url>
  </required_header>
  <id_info>
    <org_study_id>CPMCV-01-14</org_study_id>
    <nct_id>NCT02137187</nct_id>
  </id_info>
  <brief_title>Atrioventricular Junction Ablation and Biventricular Pacing for Atrial Fibrillation and Heart Failure</brief_title>
  <acronym>APAF-CRT</acronym>
  <official_title>A Randomized Controlled Trial of Atrioventricular (AV) Junction Ablation and Biventricular Pacing Versus Optimal Pharmacological Therapy in Patients With Permanent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence of superiority of AV junction ablation strategy over pharmacological
      therapy only for symptoms of atrial fibrillation, but not for heart failure, hospitalization,
      morbidity and mortality. Hypothesis of trial is that AV junction ablation is superior to
      pharmacological therapy as regard hospitalization and mortality
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized, controlled, investigator-initiated trial which consists of two
      specific consecutive(overlapped) phases:

      &quot;Morbidity trial&quot; (APAF-CRT morbidity). Small size (280 pts), follow-up 24 months. Primary
      endpoint: combined of mortality due to heartfailure, hospitalization for heart failure or
      atrial fibrillation or worsening heart failure. Predefined subgroup analysis for patients
      with ejection fraction ≤35% versus &gt;35%

      &quot;Mortality trial&quot; (APAF-CRT mortality). Large size (pts included in morbidity trial plus
      additional ~1500 pts, long-term follow-up (at least 4 years). Primary endpoint: total
      mortality. Predefined subgroup analysis for patients with ejection fraction ≤35% versus &gt;35%
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined end-point</measure>
    <time_frame>Upto 3 years</time_frame>
    <description>&quot;Morbidity trial&quot; end-points Primary end-point: a combined of (1) mortality due to heart failure, (2) hospitalization for heart failure or uncontrolled intolerable atrial fibrillation, or (3) worsening heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major clinical events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>&quot;Morbidity trial&quot; end-points Secondary end-points: total mortality, total hospitalizations, hospitalization for heart failure and/or atrial fibrillation and worsening heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major clinical events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>&quot;Mortality trial&quot; end-points Secondary end-point: cardiovascular mortality and hospitalization for heart failure or uncontrolled intolerable atrial fibrillation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1830</enrollment>
  <condition>Permanent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Drug therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device: AV junction ablation &amp; CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AV junction ablation</intervention_name>
    <description>AV junction ablation</description>
    <arm_group_label>Device: AV junction ablation &amp; CRT</arm_group_label>
    <other_name>AV nodal ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT</intervention_name>
    <description>Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)</description>
    <arm_group_label>Device: AV junction ablation &amp; CRT</arm_group_label>
    <other_name>Cardiac resynchronization therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized drug therapy</intervention_name>
    <description>Optimized drug therapy for heart failure and atrial fibrillation rate control</description>
    <arm_group_label>Drug therapy</arm_group_label>
    <arm_group_label>Device: AV junction ablation &amp; CRT</arm_group_label>
    <other_name>Pharmacological therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <description>Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines</description>
    <arm_group_label>Drug therapy</arm_group_label>
    <arm_group_label>Device: AV junction ablation &amp; CRT</arm_group_label>
    <other_name>Implantable defibrillator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible, each patient must be in the following condition:

          1. Permanent atrial fibrillation (&gt;6 months) which has been considered unsuitable for
             ablation or failed ablation

          2. Narrow QRS ≤ 110 ms

          3. Severely symptomatic (atrial fibrillation-related symptoms), refractory to drug
             therapy for rate control

          4. At least one hospitalization related to atrial fibrillation and/or heart failure in
             the previous year (see definition below)

        Exclusion Criteria:

          1. New York Heart Association (NYHA) class IV and systolic blood pressure &lt;80 mmHg
             despite optimized therapy;

          2. severe concomitant non-cardiac disease;

          3. need for surgical intervention;

          4. myocardial infarction within the previous 3 months;

          5. previous implanted devices (PM/ICD/CRT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Marsano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Brignole, MD</last_name>
    <phone>+39 0185 329567</phone>
    <email>mbrignole@asl4.liguria.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Ospedali del Tigullio</name>
      <address>
        <city>Lavagna</city>
        <zip>16033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Brignole, MD</last_name>
      <phone>0185329567</phone>
      <email>mbrignole@asl4.liguria.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol. 2012 Feb;5(1):68-76. doi: 10.1161/CIRCEP.111.967810. Epub 2011 Dec 20. Review.</citation>
    <PMID>22187425</PMID>
  </reference>
  <results_reference>
    <citation>Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011 Oct;32(19):2420-9. doi: 10.1093/eurheartj/ehr162. Epub 2011 May 23.</citation>
    <PMID>21606084</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2014</study_first_submitted>
  <study_first_submitted_qc>May 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Cardiac resynchronization therapy</keyword>
  <keyword>Implantable defibrillator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

